Kilobaser vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 39)
Kilobaser logo

Kilobaser

EmergingHealthcare

General

Vienna Austria YC W21 desktop DNA synthesizer enabling on-demand oligo production in research labs at $3.1M revenue 2024; $1.99M BioTools Innovator-backed "Nespresso for DNA" at $35.5-49.5K competing with IDT and Evonetix for benchtop DNA synthesis.

AI VisibilityBeta
Overall Score
D39
Category Rank
#410 of 596
AI Consensus
82%
Trend
up
Per Platform
ChatGPT
33
Perplexity
38
Gemini
41

About

Kilobaser is a Vienna, Austria-based biotechnology hardware company — backed by Y Combinator (W21) with $1.99 million in total funding from BioTools Innovator — providing research laboratories and life sciences companies with desktop DNA and RNA oligonucleotide synthesizers that enable individual scientists to produce custom synthetic DNA sequences directly on their benchtops without sending samples to commercial synthesis services, generating $3.1 million in annual revenue in 2024 with consistent revenue growth since the 2014 company founding. Positioned as the "Nespresso Machine for DNA," Kilobaser offers the Basic Edition synthesizer ($35,500) and Extended Edition ($49,500) — compact, affordable instruments that democratize access to on-demand DNA synthesis for research labs that need rapid turnaround on custom oligonucleotide sequences for PCR primers, CRISPR guides, sequencing adapters, and synthetic gene construction.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

39
Overall Score
93
#410
Category Rank
#1
82
AI Consensus
80
up
Trend
up
33
ChatGPT
94
38
Perplexity
89
41
Gemini
94
39
Claude
92
38
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.